In preclinical studies, Achillion has demonstrated that ACH-1625 has an excellent safety profile and a pharmacokinetic profile characterized by rapid and extensive partitioning to the liver. ACH-1625 has
The primary objective of the Phase I clinical trial is to assess safety and tolerability of an oral dose of SP-304 in healthy adult volunteers. SP-304 is an
Vision-Sciences has also announced Health Canada approval for these scopes. With Health Canada’s approval, and the approval of applicable technical files and updated EC certificates, Vision-Sciences is now
This Phase III multi-center study is led by the National Cancer Institute (NCI) and is enrolling at cancer centers throughout the US. Delcath has finalized a clinical research
Schering-Plough has licensed to ViroDefense the exclusive rights for development of a specific compound series for polio indications. The license was provided in exchange for the purchase of
The companies have also announced that they have received approval from the regulatory authorities in Denmark to initiate a second repeat-dose Phase I clinical trial of TB-403 in
These tests join Xpert MRSA, which received Health Canada license in January, 2008. In Mexico, Cepheid has received registration from the Secretary of Health for its GeneXpert System
The Ascent-2 trial was terminated by Novacea in November 2007 due to an unexplained imbalance of deaths between the treatment and control arms of the trial. Ascent-2 was
In this open-label, single-arm Phase II trial, women with platinum-resistant ovarian cancer were treated with up to six cycles of NOV-002 and carboplatin. Efficacy endpoints included progression-free survival
The agreement allows Proteomika to manufacture and use nucleic acid programmable protein array (NAPPA) technology at Proteomika’s facilities for its internal purposes and the performance of services to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.